# Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

> **NCT00697931** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 116 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Recombinant MPL- adjuvanted hepatitis B vaccine
- **BIOLOGICAL:** Engerix™-B

## Key facts

- **NCT ID:** NCT00697931
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-05
- **Primary completion:** 1998-06
- **Final completion:** 1998-06
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2008-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697931, "Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00697931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*